CCI-779

DRUG5 trials

Conditions

Carcinoma, Renal CellClear Cell Renal Cell CarcinomaKidney NeoplasmsMultiple MyelomaMultiple Sclerosis, Relapsing-RemittingRecurrent Renal Cell CancerRheumatoid ArthritisStage IV Renal Cell Cancer

Phase 1

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

CompletedNCT00112840

National Cancer Institute (NCI)Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer

Start: 2005-05-31End: 2015-09-10Updated: 2022-02-01

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

CompletedNCT00483262

Dana-Farber Cancer InstituteMultiple Myeloma

Start: 2007-05-31End: 2012-02-29Updated: 2013-11-11

Phase 2

Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy

TerminatedNCT00076206

Wyeth is now a wholly owned subsidiary of PfizerRheumatoid Arthritis

Start: 2003-12-31End: 2005-08-31Updated: 2015-12-09

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

CompletedNCT00228397

Wyeth is now a wholly owned subsidiary of PfizerMultiple Sclerosis, Relapsing-Remitting

Start: 2003-11-30End: 2005-11-30Updated: 2013-02-13

Phase 3

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

CompletedNCT00065468

PfizerCarcinoma, Renal Cell, Kidney Neoplasms

Start: 2003-07-31End: 2011-03-31Updated: 2012-10-25

Related Papers

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

2016-05-2624 citations

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.

2015-01-0761 citations

Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.

Journal of Clinical Oncology2014-02-014 citations

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

2011-02-2166 citations

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

2007-05-012635 citations